Report period | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
End date of the reporting period | ||||||
Capitalization, $ | ||||||
Capitalization, $ | ||||||
Enterprise Value | ||||||
Book Value | ||||||
Shareholders Book Value | ||||||
Current liabilities | ||||||
Noncurrent liabilities | ||||||
Total liabilities | ||||||
Debt | ||||||
Cash and cash equivalents | ||||||
Net debt | ||||||
Assets | ||||||
Total ordinary shares | ||||||
Ordinary share price |
Ticker | Name | Type | Nominal value | ISIN | Price |
---|---|---|---|---|---|
DHR:US | Danaher Corporation | Common share | - | US2358511028 | $246.1 |
Company name | Danaher |
---|---|
Tags | #s&p500 index |
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Life Sciences Tools & Services / Life Sciences Tools & Services |
Business address | 2200 PENNSYLVANIA AVE. N.W. SUITE 800W WASHINGTON DC 20037-1701 2028280850 |
Mailing address | 2200 PENNSYLVANIA AVE. N.W. SUITE 800W WASHINGTON DC 20037-1701 |
Website | www.danaher.com |
Information disclosure | www.sec.gov |